Experts Aaron Gerds and Lucia Masarova discuss key updates in myeloproliferative neoplasms (MPNs) presented at ASH 2022, including the MOMENTUM trial, combination approaches, and novel agents like calreticulin-targeting antibodies. They also explore advancements in fibrosis treatment, the role of immunotherapies in eliminating malignant clones, and challenges in MPN treatment for accelerated and blast phase diseases.